A single center, prospective, one arm clinical study to assess the tolerance and effectiveness of total body irradiation and cladribine in adult patients diagnosed with AML( acute myeloid leukemia) and myelodysplastic syndromes.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach
Gliwice, Poland
The probability of progression-free survival in 24 month follow up
Time frame: 24 month follow up
Frequency of adverse events
Time frame: 24 month follow up
24-month overall survival probability
Time frame: 24 month follow up
Disease recurrence probability.
Time frame: 24 month follow up
Mortality unrelated with disease recurrence
Time frame: 24 month follow up
Likelihood of acute and chronic graft-versus-host disease
Time frame: 24 month follow up
Time of neutrophil and platelet implantation
Time frame: 24 month follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.